Curative Effect Of Atorvastatin Combined With Ezetimibe On Coronary Heart Disease People

Statins is showed to be an effective lipid-lowing agents. It can inhibit the enzymatic activity of3-hydroxy-3methylglutaryl coenzyme A(HMG-COA) reductase competitively, then reduce the total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels and promote the LDL-C to be cleared.Inflammations are the main factors which make atheroma unstable. Statins can reduce markers of inflammation and improve endothelial function. So statins can stabilize athcroma and prevent cardiovascular events. Ezetimibe is a novel lipid-regulating agent which selectively inhibits the intestinal absorption of cholesterol. Compared with atorvastatin20mg/d, atorvastatin10mg/d combined with ezetimibe10mg/d could more significantly decrease the LDL-C levels.However, to compare the efficacy of the two treatments among coronary heart disease (CHD) people,the relevant reports of large-scare clinical research were scarce.Objective:To compare the efficacy of two treatments(atorvastatin lOmg/d combined with ezetimibe10mg/d and atorvastatin20mg/d) among coronary heart disease(CHD)people whose coronary artery stenosis was between50-70%.Methods:100coronary heart disease (CHD) patients(coronary artery stenosis between50%-70%who had not stents)were randomized to two groups:experimental group:atorvastatin10mg/d combined with ezetimibe10mg/d (n=50); control group: atorvastatin20mg/d (n=50). All patients tested the low-density lipoprotein cholesterol(LDL-C), liver function, renal function, muscle enzymes before treatment, after4weeks and after1year. Recorded the major adverse coronary events(MACE) and the revascularization in1year.Results:Both groups resulted in significant reductions in LDL-C, and the reduction of experimental group was more significant than control group.The incidences of MACE and revascularization in experimental group were less than control group, but there was no statistical difference between two groups.Conclusions:Atorvastatin10mg/d combined with ezetimibe10mg/d produced more LDL-C reductions. And it may further improve clinic prognosis of coronary heart disease patients.